User login
Key clinical point: A 3-tiered prostate cancer screening and risk stratification using a combination of prostate-specific antigen (PSA), 4-kallikrein panel, and magnetic resonance imaging (MRI) is feasible.
Major finding: The participation rate is 40%. PSA of 3 ng/mL or more was reported in 7% of men, 6% had a positive kallikrein panel, and 3% had suspicious MRI findings. Clinically significant cancer (Gleason score of ≥7) was detected in 5 men. The number needed to screen for clinically significant cancer was 32. Kallikrein panel and MRI after PSA reduced biopsy rate by 56%.
Study details: Study of 399 men invited for screening with 3 stepwise tests (PSA, kallikrein panel, and MRI).
Disclosures: This study was supported by Academy of Finland, Finnish Cancer Organisations, Jane and Aatos Erkko Foundation, and others. The authors received advisory/lecture fees, congress support, and royalties and held stocks outside this work.
Source: Rannikko A et al. BJU Int. 2021 Dec 27. doi: 10.1111/bju.15683.
Key clinical point: A 3-tiered prostate cancer screening and risk stratification using a combination of prostate-specific antigen (PSA), 4-kallikrein panel, and magnetic resonance imaging (MRI) is feasible.
Major finding: The participation rate is 40%. PSA of 3 ng/mL or more was reported in 7% of men, 6% had a positive kallikrein panel, and 3% had suspicious MRI findings. Clinically significant cancer (Gleason score of ≥7) was detected in 5 men. The number needed to screen for clinically significant cancer was 32. Kallikrein panel and MRI after PSA reduced biopsy rate by 56%.
Study details: Study of 399 men invited for screening with 3 stepwise tests (PSA, kallikrein panel, and MRI).
Disclosures: This study was supported by Academy of Finland, Finnish Cancer Organisations, Jane and Aatos Erkko Foundation, and others. The authors received advisory/lecture fees, congress support, and royalties and held stocks outside this work.
Source: Rannikko A et al. BJU Int. 2021 Dec 27. doi: 10.1111/bju.15683.
Key clinical point: A 3-tiered prostate cancer screening and risk stratification using a combination of prostate-specific antigen (PSA), 4-kallikrein panel, and magnetic resonance imaging (MRI) is feasible.
Major finding: The participation rate is 40%. PSA of 3 ng/mL or more was reported in 7% of men, 6% had a positive kallikrein panel, and 3% had suspicious MRI findings. Clinically significant cancer (Gleason score of ≥7) was detected in 5 men. The number needed to screen for clinically significant cancer was 32. Kallikrein panel and MRI after PSA reduced biopsy rate by 56%.
Study details: Study of 399 men invited for screening with 3 stepwise tests (PSA, kallikrein panel, and MRI).
Disclosures: This study was supported by Academy of Finland, Finnish Cancer Organisations, Jane and Aatos Erkko Foundation, and others. The authors received advisory/lecture fees, congress support, and royalties and held stocks outside this work.
Source: Rannikko A et al. BJU Int. 2021 Dec 27. doi: 10.1111/bju.15683.